A Prospective, Single-center Study of Comparing the Efficacy and Safety of Human Umbilical Cord Mesenchymal Stem Cells and Low-dose IL-2 in the Treatment of Lupus Nephritis
The purpose of this study is to compare the efficacy and safety of human umbilical cord mesenchymal stem cells and low-dose IL-2 in the treatment of LN
⁃ Only patients with active lupus nephritis who meet all of the following criteria are eligible for inclusion in this study:
• Before random assignment, records show that it meets at least 4 of the 11 SLE classification criteria recommended by ACR in 1997.
• Age: age \> 18 years old, ≤ 65 years old when obtaining informed consent
• SLEDAI-2K score ≥ 6
• Urinary total protein / creatinine ratio \> 1.0 or 24-hour urinary protein \> 1.0g, with or without microscopic hematuria
• If they are fertile, they must agree to use effective contraception during the trial.
• In the case of women of childbearing age, urinary pregnancy and serum pregnancy tests should be negative.
• Voluntarily sign informed consent and comply with the requirements of the research programme